A biotech company pioneering the MDMA value chain: Discover the 2 formats available
Pharmala Biotech Holdings Inc. MDMAa company focused on the research, development and manufacture of MDMA and similar class molecules, has registered a trademark for its Clinical Grade MDMA, Good Manufacturing Practices product, which will be available under the name “Laneo MDMA”.
This decision makes Pharmala the only publicly traded company for developing a comprehensive set of manufacturing stocks for MDMA to date, encompassing GMP manufacturing of Active Pharmaceutical Ingredients (APIs) and formulation of pharmaceutical products.
The company defines itself as a “regulatory first” organization, which translates to the principle that true success in the psychedelics industry will only be achieved through excellent relationships with regulators.
Pharmala’s two main goals are to provide suitable MDMA for clinical trials and to develop new drugs in the same class. In this sense, alongside the current trademark for MDMA, the company has started preclinical research on two new patented chemical entities based on MDMA-class molecules in the United States and Canada.
About the most recent resolution, the Director of Sales at Pharmala Biotech, David Purcellcommented, “We talk to customers every day who are excited to start clinical trials with MDMA, but they can’t because until now they didn’t have access to the supply of drugs for clinical trials.
Good, Laneo MDMA seems like a possible answer. Currently, the compound can be purchased in two different formats: a 40 mg clinical trial capsule or the pure active pharmaceutical ingredient to be prepared by a qualified pharmacist.
According to the company, it has already received filings from interested parties. The first product deliveries are scheduled for fall 2022.